Type 2 diabetes mellitus patients treated with either the sodium-glucose cotransporter-2 inhibitor empagliflozin or dipeptidyl peptidase 4 inhibitors incur similar overall healthcare costs, according to data from the EMPRISE trial presented at the 79th Scientific Sessions of the American Diabetes Association (ADA 2019).
Supplementation with vitamin D among vitamin D-sufficient adults who are at high risk of developing diabetes does not reduce the risk of developing the disease vs placebo, according to the randomized, placebo-controlled D2d* trial.
Once-weekly subcutaneous injections of dulaglutide in patients with type 2 diabetes (T2D) reduced cardiovascular (CV) events, particularly non-fatal stroke, regardless of their CV history in the longest cardiovascular outcomes trial (CVOT) to date for a GLP-1* receptor agonist, REWIND**. The CV benefits come with potential renal benefits, with the largest effect seen for macroalbuminuria in an exploratory analysis.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.